Rising drug overdose deaths in chronic liver disease in the United States, 2015–2023 Donghee Kim, Brittany B Dennis, Pojsakorn Danpanichkul, Karn Wijarnpreecha, George Cholankeril, Aijaz Ahmed Clinical and Molecular Hepatology.2025; 31(3): e277. CrossRef
Advancing Policy and Practice in Alcohol-Associated Liver Disease and Alcohol-Attributable Cancer: Correspondence to the editorial on “Rising Burden of Alcohol-Associated Liver Disease and Cancers: Insights into Sex Disparities and Policy Implications” Pojsakorn Danpanichkul, Donghee Kim, Karn Wijarnpreecha, Amit G. Singal, Ju Dong Yang Clinical and Molecular Hepatology.2025;[Epub] CrossRef
Extrahepatic manifestation of metabolic dysfunction-associated steatotic liver disease Anoushka Shenoy, Aijaz Ahmed, Donghee Kim Metabolism and Target Organ Damage.2025;[Epub] CrossRef
Reply to correspondence on “Current burden of steatotic liver disease and fibrosis among adults in the United States, 2017-2023” Jeayeon Park, Su Jong Yu Clinical and Molecular Hepatology.2025; 31(2): e221. CrossRef
Neonatal liver-derived FTH1-enriched extracellular vesicles attenuate ferroptosis and ameliorate MASLD pathogenesis Xin Zeng, Wei Jiang, Tian Wu, Lan Li, Fudong Fu, Han Yao, Dongbo Wu Free Radical Biology and Medicine.2025; 240: 693. CrossRef
Liver-Related COVID-19 Consequences: Dynamics of Liver Health in 2.5 Years Ieva Vanaga, Oksana Kolesova, Aleksandrs Kolesovs, Maija Radzina, Davis Simanis Putrins, Jelena Egle, Sniedze Laivacuma, Jelena Storozenko, Ludmila Viksna Journal of Clinical Medicine.2025; 14(21): 7604. CrossRef
Association of gut microbiota dietary index with metabolic dysfunction-associated steatotic liver disease: the mediating roles of inflammation and body mass index Yu Pu, Zongbiao Tan, Yanrui Wu, Suqi Zeng, Haodong He, Jixiang Zhang, Weiguo Dong Frontiers in Nutrition.2025;[Epub] CrossRef
Advances in identifying risk factors of metabolic dysfunction-associated alcohol-related liver disease Rui-Qi Ye, Yi-Fan Chen, Chang Ma, Xi Cheng, Wei Guo, Sha Li Biomedicine & Pharmacotherapy.2025; 188: 118191. CrossRef
Disproportionately rising mortality rates of alcohol-associated acute Pancreatitis: Analysis from centers for Disease Control and prevention database (2011–2020) Pojsakorn Danpanichkul, Yanfang Pang, Donghee Kim, Thanida Auttapracha, Shu-Yen Chan, Do Han Kim, Thanawin Pramotedham, Kanita Mankan, Chanokporn Puchongmart, Juan Pablo Arab, Luis Antonio Diaz, Jorge D. Machicado, Michael B. Wallace, Karn Wijarnpreecha Pancreatology.2025; 25(4): 508. CrossRef
A Comparison of the Predictive Value of 12 Body Composition Markers for Metabolic Dysfunction-Associated Steatotic Liver Disease, At-Risk Metabolic Dysfunction-Associated Steatohepatitis, and Increased Liver Stiffness in a General Population Setting Laurens A. van Kleef, Maurice Michel, Mesut Savas, Jesse Pustjens, Roel van de Laar, Edith Koehler, Elisabeth F.C. van Rossum, Harry L.A. Janssen, Jörn M. Schattenberg, Willem P. Brouwer American Journal of Gastroenterology.2025;[Epub] CrossRef
Extrahepatic manifestation of metabolic dysfunction-associated steatotic liver disease Anoushka Shenoy, Aijaz Ahmed, Donghee Kim Metabolism and Target Organ Damage.2025;[Epub] CrossRef
Organokine-Mediated Crosstalk: A Systems Biology Perspective on the Pathogenesis of MASLD—A Narrative Review Sandra Maria Barbalho, Lucas Fornari Laurindo, Vitor Engracia Valenti, Nahum Méndez-Sánchez, Mariana M. Ramírez-Mejía, Ricardo de Alvares Goulart International Journal of Molecular Sciences.2025; 26(23): 11547. CrossRef
Editorial: Understanding How Social Determinants of Health Impact Mortality in MASLD—Insights From a National Analysis. Authors' Reply Donghee Kim, Pojsakorn Danpanichkul, Karn Wijarnpreecha, Rohit Loomba, Aijaz Ahmed Alimentary Pharmacology & Therapeutics.2025;[Epub] CrossRef
Background/Aims Multi-society experts proposed the adoption of new terminology, metabolic dysfunctionassociated steatotic liver disease (MASLD) and steatotic liver disease (SLD). We studied the current prevalence of SLD and its subcategories in the US.
Methods Using the recent National Health and Nutrition Examination Survey from 2017 to 2023, we analyzed data from 12,199 participants (≥18 years) who completed transient elastography. SLD and its subcategories, including MASLD, metabolic and alcohol-related liver disease (MetALD), and alcohol-related liver disease (ALD), were categorized according to consensus nomenclature.
Results The age-adjusted prevalence of SLD (cut-off: 285 dB/m) was 35.0% (95% confidence interval [CI] 33.4–36.7). Within this category, the age-adjusted prevalence for MASLD was 31.9% (95% CI 30.4–33.4), MetALD 2.2% (95% CI 1.8–2.6), and ALD 0.8% (95% CI 0.6–1.1). The prevalence of SLD and MASLD showed a statistically insignificant decrease during COVID-19, while ALD increased without significance. In contrast, the prevalence of advanced fibrosis in SLD was significantly higher during the COVID-19 era, at 9.8% for 285 dB/m and 7.8% for 263 dB/m, compared to 7.4% (P=0.039) and 6% (P=0.041) in the pre-COVID-19 era. The proportion of advanced fibrosis and cirrhosis in individuals with ALD was two-fold higher than MASLD and MetALD, largely due to increases during the COVID-19 era.
Conclusions While the prevalence of SLD and its subcategories remained stable, there was a significant increase in advanced fibrosis among SLD individuals during the COVID-19 era, with ALD having a proportion of advanced fibrosis and cirrhosis that was twice as high as MASLD and MetALD.
Citations
Citations to this article as recorded by
Diagnostic Performance of Ultrasound-Derived Fat Fraction and Automated Point Shear Wave Elastography for Hepatic Steatosis and Fibrosis in Suspected Steatotic Liver Disease: A Prospective Multicenter Study Jing Liang, Xueqi Li, Guangwen Cheng, Huixiong Xu, Yuli Zhu, Zhe Ma, Dong Jiang, Hao Han, Lin Chen, Liyun Xue, Xiaohui Qiao, Hong Ding Ultrasound in Medicine & Biology.2026; 52(1): 227. CrossRef
Current Burden of Lean Metabolic Dysfunction‐Associated Steatotic Liver Disease Among US Adults, 2017–2023 Donghee Kim, Pojsakorn Danpanichkul, Karn Wijarnpreecha, George Cholankeril, Rohit Loomba, Aijaz Ahmed Alimentary Pharmacology & Therapeutics.2025; 61(5): 891. CrossRef
Editorial: Steatotic Liver Diseases Emerge as Rapidly Growing Drivers of Primary Liver Cancer in the United States—Author's Reply Pojsakorn Danpanichkul, Donghee Kim, Chun Wei Pan, Amit G. Singal, Ju Dong Yang, Karn Wijarnpreecha Alimentary Pharmacology & Therapeutics.2025; 61(6): 1059. CrossRef
Cigarette Smoke Contributes to the Progression of MASLD: From the Molecular Mechanisms to Therapy Jiatong Xu, Yifan Li, Zixuan Feng, Hongping Chen Cells.2025; 14(3): 221. CrossRef
Alcohol–Related Liver Disease, Followed by Metabolic Dysfunction–Associated Steatotic Liver Disease, Emerges as the Fastest‐Growing Aetiologies for Primary Liver Cancer in the United States Pojsakorn Danpanichkul, Kwanjit Duangsonk, Markos Kalligeros, Michael B. Fallon, Chawinthorn Vuthithammee, Chun Wei Pan, Preenapun Saokhieo, William Derrick, Yanfang Pang, Vincent L. Chen, Donghee Kim, Amit G. Singal, Ju Dong Yang, Karn Wijarnpreecha Alimentary Pharmacology & Therapeutics.2025; 61(6): 959. CrossRef
Association of High‐Sensitivity Troponins in Metabolic Dysfunction‐Associated Steatotic Liver Disease With All‐Cause and Cause‐Specific Mortality Donghee Kim, Pojsakorn Danpanichkul, Karn Wijarnpreecha, George Cholankeril, Aijaz Ahmed Alimentary Pharmacology & Therapeutics.2025; 61(11): 1785. CrossRef
Revealing the importance of a multidisciplinary approach to reducing the global burden of SLD through the COVID-19 pandemic: Editorial on “Current burden of steatotic liver disease and fibrosis among adults in the United States, 2017–2023” Jeayeon Park, Su Jong Yu Clinical and Molecular Hepatology.2025; 31(2): 625. CrossRef
The burden of steatotic liver disease before and during the COVID-19 pandemic: Correspondence to editorial on “Current burden of steatotic liver disease and fibrosis among adults in the United States, 2017-2023” Donghee Kim, Pojsakorn Danpanichkul, Karn Wijarnpreecha, George Cholankeril, Rohit Loomba, Aijaz Ahmed Clinical and Molecular Hepatology.2025; 31(2): e183. CrossRef
Reply to correspondence on “Current burden of steatotic liver disease and fibrosis among adults in the United States, 2017-2023” Jeayeon Park, Su Jong Yu Clinical and Molecular Hepatology.2025; 31(2): e221. CrossRef
Vibration-controlled transient elastography in shaping the epidemiology and management of steatotic liver disease: Editorial on “Current burden of steatotic liver disease and fibrosis among adults in the United States, 2017–2023” Xiao-Dong Zhou, Terry Cheuk-Fung Yip, Daniel Q Huang, Mark Dhinesh Muthiah, Mazen Noureddin, Ming-Hua Zheng Clinical and Molecular Hepatology.2025; 31(2): 620. CrossRef
Addressing the burden of steatotic liver disease: The role of transient elastography: Correspondence to editorial on “Current burden of steatotic liver disease and fibrosis among adults in the United States, 2017-2023” Donghee Kim, Pojsakorn Danpanichkul, Karn Wijarnpreecha, George Cholankeril, Rohit Loomba, Aijaz Ahmed Clinical and Molecular Hepatology.2025; 31(2): e180. CrossRef
Correspondence to editorial on “Global epidemiology of alcohol-related liver disease, liver cancer, and alcohol use disorder, 2000-2021” Pojsakorn Danpanichkul, Luis Antonio Diaz, Kanokphong Suparan, Karn Wijarnpreecha, Juan Pablo Arab Clinical and Molecular Hepatology.2025; 31(2): e200. CrossRef
Advances in identifying risk factors of metabolic dysfunction-associated alcohol-related liver disease Rui-Qi Ye, Yi-Fan Chen, Chang Ma, Xi Cheng, Wei Guo, Sha Li Biomedicine & Pharmacotherapy.2025; 188: 118191. CrossRef
The Role of Global Physical Capacity Score in Key Parameters of Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) Nicola Verrelli, Caterina Bonfiglio, Isabella Franco, Claudia Beatrice Bagnato, Dolores Stabile, Endrit Shahini, Antonella Bianco Journal of Clinical Medicine.2025; 14(11): 3821. CrossRef
Evolving Public Attention to Steatotic Liver Disease: A 20‐Year Analysis (2004–2024) Pojsakorn Danpanichkul, Charat Thongprayoon, Kanokphong Suparan, Donghee Kim, Ornpailin Wanichthanaolan, Phuuwadith Wattanachayakul, Yanfang Pang, Mark D. Muthiah, Anand V. Kulkarni, Ju Dong Yang, Apichat Kaewdech, Wisit Cheungpasitporn, Karn Wijarnpreech Journal of Gastroenterology and Hepatology.2025; 40(8): 2053. CrossRef
The association between sedentary behavior and MASLD in overweight and obese adults: investigating the role of inflammatory markers using NHANES data (2017–March 2020) Zehong Zhou, Linfang Li, Chusi Wang, Shiqi Li, Pengfei Chen, Jiesheng Huang, Ming Peng Frontiers in Nutrition.2025;[Epub] CrossRef
Current burden of MASLD, MetALD, and hepatic fibrosis among US adults with prediabetes and diabetes, 2017–2023 Donghee Kim, Rohit Loomba, Aijaz Ahmed Clinical and Molecular Hepatology.2025; 31(3): e235. CrossRef
Contemporary burden of mortality from chronic liver disease by sex and race/ethnicity in the United States Donghee Kim, Pojsakorn Danpanichkul, Karn Wijarnpreecha, George Cholankeril, Aijaz Ahmed Clinical and Molecular Hepatology.2025; 31(3): e268. CrossRef
Persistent Binge Drinking History Associated With Advanced Liver Fibrosis and All‐Cause Mortality in MetALD Zhe‐Kun Xiong, Ru‐Tao Lin, Bi‐Wei Chen, Xin Xin, Tao‐Ying Deng, Qin‐Mei Sun, Yi‐Yang Hu, Li‐Ming Gan, Qin Feng Alimentary Pharmacology & Therapeutics.2025; 62(11-12): 1100. CrossRef
Advancing Policy and Practice in Alcohol-Associated Liver Disease and Alcohol-Attributable Cancer: Correspondence to the editorial on “Rising Burden of Alcohol-Associated Liver Disease and Cancers: Insights into Sex Disparities and Policy Implications” Pojsakorn Danpanichkul, Donghee Kim, Karn Wijarnpreecha, Amit G. Singal, Ju Dong Yang Clinical and Molecular Hepatology.2025;[Epub] CrossRef
A Novel Risk Prediction Model for Hepatocellular Carcinoma in MASLD: A Multinational, Multicenter Cohort Study Ho Soo Chun, Minjong Lee, Hye Ah Lee, Eun Seo Park, Jeong Yoon Choi, Hyo Song Baek, Tae Hun Kim, Huapeng Lin, Terry Cheuk-Fung Yip, Hye Won Lee, Emmanuel Tsochatzis, Salvatore Petta, Elisabetta Bugianesi, Masato Yoneda, Ming-Hua Zheng, Hannes Hagström, Jé Clinical Gastroenterology and Hepatology.2025;[Epub] CrossRef
Effect of varenicline on major adverse liver outcomes in alcohol‐associated liver disease: An exploratory analysis Pojsakorn Danpanichkul, Yanfang Pang, Donghee Kim, Thanathip Suenghataiphorn, Donghyun Ko, Andrew F. Ibrahim, Vitchapong Prasitsumrit, Kwanjit Duangsonk, Mazen Noureddin, Karn Wijarnpreecha, Suthat Liangpunsakul Alcohol, Clinical and Experimental Research.2025; 49(11): 2451. CrossRef
The effects of ellagic acid in metabolic dysfunction-associated steatotic liver disease (MASLD) patients: a randomized, add-on, double-blind, controlled trial Mohammad Mahmoudi Azar, Matin Shirazinia, Mohsen Nematy, Vafa Baradaran Rahimi, Motahare Bateni, Fateme Tafaghodi Piadeh Gheibi, Farnood Rajabzadeh, Ladan Goshayeshi, Sara Honari, Mehran Mottahedi, Vahid Reza Askari Inflammopharmacology.2025; 33(9): 5583. CrossRef
Dietary vitamin E intake in metabolic dysfunction–associated steatotic liver disease and all-cause/cause-specific mortality Donghee Kim, Pojsakorn Danpanichkul, Karn Wijarnpreecha, Aijaz Ahmed European Journal of Gastroenterology & Hepatology.2025;[Epub] CrossRef
Letter to the Editor on “Current Burden of Steatotic Liver Disease and Fibrosis among Adults in the United States, 2017-2023” Sisi Yang, Zhenxuan Ma Clinical and Molecular Hepatology.2025;[Epub] CrossRef
Non‐Response to Obeticholic Acid Is Associated With Heightened Risks of Developing Clinical Events in Primary Biliary Cholangitis Nadir Abbas, Rachel Smith, Ellina Lytvyak, Miki Scaravaglio, Neil Halliday, Amal Almahroos, Nadia Eden, Diane Lloyd‐Madden, Sanchit Sharma, James Ferguson, Jessica K. Dyson, Douglas Thorburn, David Jones, Aldo J. Montano‐Loza, Marco Carbone, Pietro Invern Alimentary Pharmacology & Therapeutics.2025;[Epub] CrossRef
Extrahepatic manifestation of metabolic dysfunction-associated steatotic liver disease Anoushka Shenoy, Aijaz Ahmed, Donghee Kim Metabolism and Target Organ Damage.2025;[Epub] CrossRef
Class-Specific Effects of ARBs Versus ACE Inhibitors on Survival and Cardiovascular Outcomes in MASLD Tom Ryu, Yeon Joo Seo, Jaejun Lee, Ji Won Han, Hyun Yang, Keungmo Yang International Journal of Molecular Sciences.2025; 26(20): 10061. CrossRef
Social Determinants of Health in Metabolic Dysfunction‐Associated Steatotic Liver Disease and All‐Cause/Cause‐Specific Mortality Donghee Kim, Pojsakorn Danpanichkul, Karn Wijarnpreecha, Rohit Loomba, Aijaz Ahmed Alimentary Pharmacology & Therapeutics.2025;[Epub] CrossRef
Editorial: Understanding How Social Determinants of Health Impact Mortality in MASLD—Insights From a National Analysis. Authors' Reply Donghee Kim, Pojsakorn Danpanichkul, Karn Wijarnpreecha, Rohit Loomba, Aijaz Ahmed Alimentary Pharmacology & Therapeutics.2025;[Epub] CrossRef
One-third of adults across the globe exhibit metabolic dysfunction-associated steatotic liver disease (MASLD)―formerly known as nonalcoholic fatty liver disease (NAFLD). To date, MASLD is the fastest-growing etiology of chronic liver disease and hepatocellular carcinoma (HCC). Besides the population with obesity, MASLD can also be found in lean populations, accounting for 13% of the global population, especially Asians. Notably, individuals with lean MASLD face equal or higher overall mortality rates compared to their non-lean counterparts. Risk modifiers encompass advanced age, hepatic fibrosis, and type 2 diabetes mellitus (T2DM). Moreover, the population with lean MASLD is associated with an increased risk of HCC, while their non-lean counterparts are more prone to cardiovascular outcomes and T2DM. Existing evidence indicates a similar risk of liver-related events and extrahepatic cancer between the two groups. However, MASLD-related genetic variants, such as PNPLA3 and TM6SF2, did not significantly affect mortality between the two populations. Still, underreporting alcohol consumption and regional representation limits the study’s comprehensiveness. Longitudinal studies and mechanistic explorations are needed to understand differences in lean versus non-lean MASLD populations. This review highlights the need for awareness and tailored interventions in managing MASLD, considering lean individuals’ unique risks.
Citations
Citations to this article as recorded by
Dietary vitamin E intake in metabolic dysfunction–associated steatotic liver disease and all-cause/cause-specific mortality Donghee Kim, Pojsakorn Danpanichkul, Karn Wijarnpreecha, Aijaz Ahmed European Journal of Gastroenterology & Hepatology.2026; 38(1): 63. CrossRef
Phthalates exposure, biological aging, and increased risks of insulin resistance, prediabetes, and diabetes in adults with metabolic dysfunction-associated steatotic liver disease Yueru Yang, Shuhui Wan, Linling Yu, Wei Liu, Jiahao Song, Da Shi, Yongfang Zhang, Weihong Chen, Weihong Qiu, Bin Wang Diabetes & Metabolism.2025; 51(1): 101602. CrossRef
Increased MASH-associated liver cancer in younger demographics Pojsakorn Danpanichkul, Yanfang Pang, Kanokphong Suparan, Thanida Auttapracha, Supapitch Sirimangklanurak, Abdelrahman M. Attia, Chanattha Thimphitthaya, Michelle Shi Ni Law, Zhenning Yu, Mostafa A. Soliman, Natchaya Polpichai, Chanakarn Kanitthamniyom, D Hepatology Communications.2025;[Epub] CrossRef
Alcohol–Related Liver Disease, Followed by Metabolic Dysfunction–Associated Steatotic Liver Disease, Emerges as the Fastest‐Growing Aetiologies for Primary Liver Cancer in the United States Pojsakorn Danpanichkul, Kwanjit Duangsonk, Markos Kalligeros, Michael B. Fallon, Chawinthorn Vuthithammee, Chun Wei Pan, Preenapun Saokhieo, William Derrick, Yanfang Pang, Vincent L. Chen, Donghee Kim, Amit G. Singal, Ju Dong Yang, Karn Wijarnpreecha Alimentary Pharmacology & Therapeutics.2025; 61(6): 959. CrossRef
Current Burden of Lean Metabolic Dysfunction‐Associated Steatotic Liver Disease Among US Adults, 2017–2023 Donghee Kim, Pojsakorn Danpanichkul, Karn Wijarnpreecha, George Cholankeril, Rohit Loomba, Aijaz Ahmed Alimentary Pharmacology & Therapeutics.2025; 61(5): 891. CrossRef
Comparative application of MAFLD and MASLD diagnostic criteria on NAFLD patients: insights from a single-center cohort Maha Elsabaawy, Madiha Naguib, Ahmed Abuamer, Ahmed Shaban Clinical and Experimental Medicine.2025;[Epub] CrossRef
Advanced lung cancer inflammation index: a key predictor of hepatic steatosis and fibrosis severity Yajie Liu, Ruilin Wang BMC Gastroenterology.2025;[Epub] CrossRef
Association of High‐Sensitivity Troponins in Metabolic Dysfunction‐Associated Steatotic Liver Disease With All‐Cause and Cause‐Specific Mortality Donghee Kim, Pojsakorn Danpanichkul, Karn Wijarnpreecha, George Cholankeril, Aijaz Ahmed Alimentary Pharmacology & Therapeutics.2025; 61(11): 1785. CrossRef
Addressing the burden of steatotic liver disease: The role of transient elastography: Correspondence to editorial on “Current burden of steatotic liver disease and fibrosis among adults in the United States, 2017-2023” Donghee Kim, Pojsakorn Danpanichkul, Karn Wijarnpreecha, George Cholankeril, Rohit Loomba, Aijaz Ahmed Clinical and Molecular Hepatology.2025; 31(2): e180. CrossRef
Current burden of steatotic liver disease and fibrosis among adults in the United States, 2017–2023 Donghee Kim, Pojsakorn Danpanichkul, Karn Wijarnpreecha, George Cholankeril, Rohit Loomba, Aijaz Ahmed Clinical and Molecular Hepatology.2025; 31(2): 382. CrossRef
Liver cirrhosis in metabolic dysfunction-associated steatohepatitis Donghyun Ko, Do Han Kim, Pojsakorn Danpanichkul, Masahito Nakano, Chitchai Rattananukrom, Karn Wijarnpreecha, Cheng Han Ng, Mark D Muthiah Gastroenterology Report.2025;[Epub] CrossRef
Advances in identifying risk factors of metabolic dysfunction-associated alcohol-related liver disease Rui-Qi Ye, Yi-Fan Chen, Chang Ma, Xi Cheng, Wei Guo, Sha Li Biomedicine & Pharmacotherapy.2025; 188: 118191. CrossRef
Increased Mortality Among Lean Versus Non‐Lean Adults With MASLD: A Multicenter Study Leith Ghani, Majd B. Aboona, Claire S. Faulkner, Pooja Rangan, Moises Nevah Rubin, Ma Ai Thanda Han, Michael B. Fallon, Vincent L. Chen, Karn Wijarnpreecha Journal of Gastroenterology and Hepatology.2025; 40(8): 1919. CrossRef
Evolving Public Attention to Steatotic Liver Disease: A 20‐Year Analysis (2004–2024) Pojsakorn Danpanichkul, Charat Thongprayoon, Kanokphong Suparan, Donghee Kim, Ornpailin Wanichthanaolan, Phuuwadith Wattanachayakul, Yanfang Pang, Mark D. Muthiah, Anand V. Kulkarni, Ju Dong Yang, Apichat Kaewdech, Wisit Cheungpasitporn, Karn Wijarnpreech Journal of Gastroenterology and Hepatology.2025; 40(8): 2053. CrossRef
Meta‐Analysis: Effects of Steatotic Liver Disease‐Associated Genetic Risk Alleles on Longitudinal Outcomes Matthew Kubina, Vitchapong Prasitsumrit, Jarell Tan, Joo Wei Ethan Quek, Dhiraj Peddu, Ankit Mishra, Pojsakorn Danpanichkul, Jake P. Mann, Eric Trépo, Stephan Buch, Daniel Q. Huang, Cheng Han Ng, Mark D. Muthiah, Yu Jun Wong, Karn Wijarnpreecha, Vincent L Alimentary Pharmacology & Therapeutics.2025; 62(3): 244. CrossRef
Metabolic Impact of Alcohol Consumption in MASLD: Understanding MetALD and Beyond Eva Juárez-Hernández, Montserrat Berrospe-Alfaro, Misael Uribe, Iván López-Mendez Journal of Clinical and Experimental Hepatology.2025; 15(6): 103114. CrossRef
Current burden of MASLD, MetALD, and hepatic fibrosis among US adults with prediabetes and diabetes, 2017–2023 Donghee Kim, Rohit Loomba, Aijaz Ahmed Clinical and Molecular Hepatology.2025; 31(3): e235. CrossRef
Predicting the risk of lean non-alcoholic fatty liver disease based on interpretable machine models in a Chinese T2DM population Shixue Bao, Qiankai Jin, Tieqiao Wang, Yushan Mao, Guoqing Huang Frontiers in Endocrinology.2025;[Epub] CrossRef
Effect of varenicline on major adverse liver outcomes in alcohol‐associated liver disease: An exploratory analysis Pojsakorn Danpanichkul, Yanfang Pang, Donghee Kim, Thanathip Suenghataiphorn, Donghyun Ko, Andrew F. Ibrahim, Vitchapong Prasitsumrit, Kwanjit Duangsonk, Mazen Noureddin, Karn Wijarnpreecha, Suthat Liangpunsakul Alcohol, Clinical and Experimental Research.2025; 49(11): 2451. CrossRef
Paradoxical association between steatotic liver disease and favorable hepatic outcomes in HCV patients with SVRs Ming-Ling Chang, Jur-Shan Cheng, Jennifer Tai, Wei-Ting Chen, Sien-Sing Yang, Cheng-Hsun Chiu, Rong-Nan Chien, Chia-Lin Hsu, Shang-Jung Wu, Cathy SJ Fann Hepatology International.2025;[Epub] CrossRef
Extrahepatic manifestation of metabolic dysfunction-associated steatotic liver disease Anoushka Shenoy, Aijaz Ahmed, Donghee Kim Metabolism and Target Organ Damage.2025;[Epub] CrossRef
Obesity-Driven Metabolic Disorders: The Interplay of Inflammation and Mitochondrial Dysfunction Wooyoung Choi, Gun Ha Woo, Tae-Hwan Kwon, Jae-Han Jeon International Journal of Molecular Sciences.2025; 26(19): 9715. CrossRef
Social Determinants of Health in Metabolic Dysfunction‐Associated Steatotic Liver Disease and All‐Cause/Cause‐Specific Mortality Donghee Kim, Pojsakorn Danpanichkul, Karn Wijarnpreecha, Rohit Loomba, Aijaz Ahmed Alimentary Pharmacology & Therapeutics.2025;[Epub] CrossRef
Metabolic dysfunction-associated steatotic liver disease: Prevalence and progression in lean patients Gerard Stupecki, Emilia Kowalczyk, Agnieszka Ciba-Stemplewska, Magdalena Dolecka-Ślusarczyk, Iwona Gorczyca-Głowacka Polish Annals of Medicine.2025; : 1. CrossRef
Increasing Prevalence of Steatotic Liver Disease in a Japanese Health Checkup Population, 2004–2022 Yuki Nakahata, Takao Miwa, Akihiro Obora, Takao Kojima, Nobuaki Yagi, Masahito Shimizu Liver International.2025;[Epub] CrossRef
The global landscape of lean metabolic dysfunction-associated steatotic liver disease: insight from Asia and the West Hery Djagat Purnomo, Randy Adiwinata, Cecilia Oktaria Permatadewi, Hesti Triwahyu Hutami, Didik Indiarso Frontiers in Gastroenterology.2025;[Epub] CrossRef
Role of ChREBP–PPARα–FGF21 Axis in Metabolic Dysfunction of MASLD Karina Mireya Palacios Girón, Zamira Helena Hernandez Nazara, Montserrat Maldonado-González, Erika Martínez-López, Martha P. Sánchez Muñoz, Carlos Alfredo Bautista López, Ma. Soledad Aldana Aguiñaga, Jose Alfredo Dominguez-Rosales, Belinda Vargas-Guerrero International Journal of Molecular Sciences.2025; 26(23): 11425. CrossRef
Implication of the Androgen Receptor in Muscle–Liver Crosstalk: An Overlooked Mechanistic Link in Lean-MASLD Eleni Myrto Trifylli, Christiana Charalambous, Nikolaos Spiliotopoulos, Nikolaos Papadopoulos, Anastasia Oikonomou, Spilios Manolakopoulos, Melanie Deutsch Livers.2025; 5(4): 65. CrossRef
PNPLA3 as a driver of steatotic liver disease: navigating from pathobiology to the clinics via epidemiology Ralf Weiskirchen, Amedeo Lonardo Journal of Translational Genetics and Genomics.2024; 8(4): 355. CrossRef
Correspondence to letter to the editor on “Contemporary awareness of viral hepatitis between 2012 and 2022 among Korean adults” Chang Hun Lee, In Hee Kim, Sook-Hyang Jeong Clinical and Molecular Hepatology.2025; 31(2): e149. CrossRef
Backgrounds/Aims The trends in mortality of hepatocellular carcinoma (HCC) and biliary tract cancers stratified by sex and race/ethnicity in the US continue to evolve. We estimated the sex- and race/ethnicity-based trends in HCC and biliary tract cancers-related mortality in US adults with a focus on disease burden.
Methods We performed a population-based analysis using the US national mortality records from 2018 to 2023. We identified HCC and biliary tract cancer using appropriate ICD-10 codes. Temporal trends in mortality were calculated by joinpoint analysis with annual percentage change (APC).
Results Annual age-standardized mortality from HCC decreased steadily with an APC of –1.4% (95% confidence interval [CI]: –2.0% to –0.7%). While there was a linear increase in intrahepatic cholangiocarcinoma-related mortality (APC: 3.1%, 95% CI: 1.2–4.9%) and ampulla of Vater cancer-related mortality (APC: 4.1%, 95% CI: 0.5–7.9%), gallbladder cancer-related mortality decreased (APC: –1.9%, 95% CI: –3.8% to –0.0%). Decreasing trends in mortality from HCC were noted in males, not females. HCC-related mortality decreased more steeply in racial and ethnic minority individuals compared with non-Hispanic White individuals. Racial and ethnic differences in trends in mortality for biliary tract cancers depended on the malignancy’s anatomical site.
Conclusions While the annual mortality for HCC and gallbladder cancer demonstrated declining trends, ICC- and AVC-related mortality continued to increase from 2018 to 2023. Although racial and ethnic minority individuals in the US experienced disproportionately higher HCC and biliary tract cancer, recent declines in HCC may be primarily due to declines among racial and ethnic minority individuals and males.
Citations
Citations to this article as recorded by
Global Burden, Trends, and Inequalities of Gallbladder and Biliary Tract Cancer, 1990–2021: A Decomposition and Age–Period–Cohort Analysis Sen Lei, Guizhong Huang, Xiaohui Li, Pu Xi, Zehui Yao, Xiaojun Lin Liver International.2025;[Epub] CrossRef
Alcohol–Related Liver Disease, Followed by Metabolic Dysfunction–Associated Steatotic Liver Disease, Emerges as the Fastest‐Growing Aetiologies for Primary Liver Cancer in the United States Pojsakorn Danpanichkul, Kwanjit Duangsonk, Markos Kalligeros, Michael B. Fallon, Chawinthorn Vuthithammee, Chun Wei Pan, Preenapun Saokhieo, William Derrick, Yanfang Pang, Vincent L. Chen, Donghee Kim, Amit G. Singal, Ju Dong Yang, Karn Wijarnpreecha Alimentary Pharmacology & Therapeutics.2025; 61(6): 959. CrossRef
Increased MASH-associated liver cancer in younger demographics Pojsakorn Danpanichkul, Yanfang Pang, Kanokphong Suparan, Thanida Auttapracha, Supapitch Sirimangklanurak, Abdelrahman M. Attia, Chanattha Thimphitthaya, Michelle Shi Ni Law, Zhenning Yu, Mostafa A. Soliman, Natchaya Polpichai, Chanakarn Kanitthamniyom, D Hepatology Communications.2025;[Epub] CrossRef
Contemporary awareness of viral hepatitis between 2012 and 2022 among Korean adults Donghee Kim, Won Kim, Aijaz Ahmed Clinical and Molecular Hepatology.2025; 31(1): e5. CrossRef
Long-term outcomes and risk modifiers of metabolic dysfunction-associated steatotic liver disease between lean and non-lean populations Pojsakorn Danpanichkul, Kanokphong Suparan, Vitchapong Prasitsumrit, Aijaz Ahmed, Karn Wijarnpreecha, Donghee Kim Clinical and Molecular Hepatology.2025; 31(1): 74. CrossRef
From past to pandemic: Health disparities in US hepatobiliary cancer mortality before and during COVID-19: Editorial on “Burden of mortality from hepatocellular carcinoma and biliary tract cancers by race and ethnicity and sex in US, 2018–2023” Ilona Argirion Clinical and Molecular Hepatology.2025; 31(1): 286. CrossRef
The burden of steatotic liver disease before and during the COVID-19 pandemic: Correspondence to editorial on “Current burden of steatotic liver disease and fibrosis among adults in the United States, 2017-2023” Donghee Kim, Pojsakorn Danpanichkul, Karn Wijarnpreecha, George Cholankeril, Rohit Loomba, Aijaz Ahmed Clinical and Molecular Hepatology.2025; 31(2): e183. CrossRef
Integrating expert knowledge with machine learning for AI-based stroke identifications and treatment systems Taddesse kassu Yimenu, Abebe Belay Adege, Sofonias Yitagesu Techan DIGITAL HEALTH.2025;[Epub] CrossRef
Contemporary burden of mortality from chronic liver disease by sex and race/ethnicity in the United States Donghee Kim, Pojsakorn Danpanichkul, Karn Wijarnpreecha, George Cholankeril, Aijaz Ahmed Clinical and Molecular Hepatology.2025; 31(3): e268. CrossRef
Rising drug overdose deaths in chronic liver disease in the United States, 2015–2023 Donghee Kim, Brittany B Dennis, Pojsakorn Danpanichkul, Karn Wijarnpreecha, George Cholankeril, Aijaz Ahmed Clinical and Molecular Hepatology.2025; 31(3): e277. CrossRef
Epidemiological trends and burden of gallbladder and biliary tract cancer in Belt and Road Initiative countries: A comprehensive analysis from the Global Burden of Disease 2021 database Hao Wu, Qian-Qian Feng, Jian-Hui Li, Hai-Yang Xie, Shi-Gui Yang, Shu-Sen Zheng Hepatobiliary & Pancreatic Diseases International.2025; 24(6): 666. CrossRef
Extrahepatic manifestation of metabolic dysfunction-associated steatotic liver disease Anoushka Shenoy, Aijaz Ahmed, Donghee Kim Metabolism and Target Organ Damage.2025;[Epub] CrossRef
Paired snRNA-seq and scRNA-seq analysis of MASLD patients to identify early-stage markers for disease progression Suebin Park, Su-Hyeon Lee, Se-eun Han, Beom Kyung Kim, Byungjin Hwang Hepatology Communications.2025;[Epub] CrossRef
Construction and validation of a novel prognostic model for postoperative patients with stage I intrahepatic cholangiocarcinoma: a population-based study Xiaomeng Yao, Xinru Fan, Qing Wang, Huabang Zhou, Hui Wang, Heping Hu Langenbeck's Archives of Surgery.2025;[Epub] CrossRef
Even Lower Alcohol Intake Might Be Harmful for East Asian Males With MASLD Spectrum Byungyoon Yun, Juyeon Oh, Heejoo Park, Jian Lee, Beom Kyung Kim, Jin-Ha Yoon Clinical Gastroenterology and Hepatology.2025;[Epub] CrossRef
Targeting ferroptosis and cuproptosis in gastrointestinal cancers: molecular mechanisms, metabolic vulnerabilities, and therapeutic interventions Yang Zhang, Yixiang Gu, Ming Zhan, Linhua Yang, Hui Wang Molecular Biomedicine.2025;[Epub] CrossRef
Editorial: Understanding How Social Determinants of Health Impact Mortality in MASLD—Insights From a National Analysis. Authors' Reply Donghee Kim, Pojsakorn Danpanichkul, Karn Wijarnpreecha, Rohit Loomba, Aijaz Ahmed Alimentary Pharmacology & Therapeutics.2025;[Epub] CrossRef
Integrative genomic and transcriptomic profiling identifies HSPA5 as a central player in hepatocellular carcinoma pathogenesis Taimoor Riaz, Sumbal Rasheed, Muhammad Zubair Computational Biology and Chemistry.2026; 120: 108722. CrossRef
Diagnostic Test Accuracy of Contrast‐Enhanced Ultrasound With Sonazoid for Assessment of Focal Liver Lesions: A Systematic Review and Meta‐Analysis Yongqing Tang, Shun‐ichi Sasaki, Joshua Hawley, Aurélie Peillon, Anders Sjöström, Adolfo Fuentes‐Alburo, Francois Tranquart Journal of Clinical Ultrasound.2025; 53(3): 510. CrossRef
Contemporary awareness of viral hepatitis between 2012 and 2022 among Korean adults Donghee Kim, Won Kim, Aijaz Ahmed Clinical and Molecular Hepatology.2025; 31(1): e5. CrossRef
Long-term outcomes and risk modifiers of metabolic dysfunction-associated steatotic liver disease between lean and non-lean populations Pojsakorn Danpanichkul, Kanokphong Suparan, Vitchapong Prasitsumrit, Aijaz Ahmed, Karn Wijarnpreecha, Donghee Kim Clinical and Molecular Hepatology.2025; 31(1): 74. CrossRef
Dual-Functional Micelles for Codelivery of Sorafenib and Dehydrodiisoeugenol in Treatment of Hepatocellular Carcinoma Su-Yu Yang, Shu-Tong Li, Tian-Hua Li, De-Jin Ma, Jun-Jie Yu, Yang Liu, Yang Yu, Xue-Tao Li, Juan Zang, Zi-Min Yuan, Liang Kong ACS Applied Nano Materials.2025; 8(11): 5355. CrossRef
Global burden of HBV-related liver disease: Primary liver cancer due to chronic HBV infection increased in over one-third of countries globally from 2000 to 2021 Pojsakorn Danpanichkul, Kwanjit Duangsonk, Vincent L. Chen, Preenapun Saokhieo, Disatorn Dejvajara, Banthoon Sukphutanan, Majd B. Aboona, Chawin Lopimpisuth, Yanfang Pang, Andrew F. Ibrahim, Michael B. Fallon, Daniel Q. Huang, Donghee Kim, Amit G. Singal, Hepatology.2025; 82(5): 1274. CrossRef
A Novel Nuclear-Localized Micropeptide, MP60, Promotes Hepatocellular Carcinoma Progression via the Epithelial-Mesenchymal Transition Chencheng Li, Xiu Hong, Sarra Setrerrahmane, Xiaoyi Sun, Xue Zhang, Hanmei Xu Cancers.2025; 17(17): 2932. CrossRef
MicroRNA-372-3p impairs fatty acid metabolism in hepatocellular carcinoma cells by targeting CPT1A and ACSL4 Chinnatam Phetkong, Thammachanok Boonto, Pannathon Thamjamrassri, Chaiyaboot Ariyachet, Pisit Tangkijvanich BioImpacts.2025; 15: 31075. CrossRef
Social Determinants of Health in Metabolic Dysfunction‐Associated Steatotic Liver Disease and All‐Cause/Cause‐Specific Mortality Donghee Kim, Pojsakorn Danpanichkul, Karn Wijarnpreecha, Rohit Loomba, Aijaz Ahmed Alimentary Pharmacology & Therapeutics.2025;[Epub] CrossRef
Validation of prognostic models for predicting postsurgical outcomes in intrahepatic cholangiocarcinoma patients using a multicenter cohort Dong Hwan Kim, Sang Hyun Choi, Sehee Kim, Woohyung Lee, Hyung-Don Kim, Hyungjin Rhee, Eun-Suk Cho, Suk-Keu Yeom, Sumi Park, Seung Soo Lee, Mi-Suk Park International Journal of Surgery.2025; 111(10): 7032. CrossRef
Multidisciplinary comprehensive treatment of massive hepatocellular carcinoma with hemorrhage: A case report and review of literature Xian-Shuai Kou, Fan-Fan Li, Yun Meng, Jian-Ming Zhao, Sheng-Fen Liu, Lan Zhang World Journal of Gastrointestinal Oncology.2024; 16(5): 2225. CrossRef
Evaluation of different scoring systems for repeating Transarterial Chemoembolization in Egyptian patients with Hepatocellular Carcinoma Omkolsoum Alhaddad, Asmaa Gomaa, Merhan El Shamandy, Mohamed Kohla, Ahmed Edrees, Reham Ashour Romanian Journal of Internal Medicine.2024; 62(4): 430. CrossRef
Phytochemicals and Their Nanoformulations for Targeting Hepatocellular Carcinoma: Exploring Potential and Targeting Strategies Safia Obaidur Rab, R. Roopashree, Farag M. A. Altalbawy, M. Ravi Kumar, Mamata Chahar, Manmeet Singh, Aziz Kubaev, Hassan Thoulfikar A. Alamir, Faraj Mohammed, Abed J. Kadhim, Merwa Alhadrawi Cell Biochemistry and Function.2024;[Epub] CrossRef
Modulation of gut microbiota by probiotics to improve the efficacy of immunotherapy in hepatocellular carcinoma Ping Chen, Chengchen Yang, Ke Ren, Mingzhi Xu, Chenwei Pan, Xuewei Ye, Lanjuan Li Frontiers in Immunology.2024;[Epub] CrossRef
Current epidemiology of chronic liver disease Richie Manikat, Aijaz Ahmed, Donghee Kim Gastroenterology Report.2023;[Epub] CrossRef
Nonalcoholic fatty liver disease (NAFLD) is the most common cause of chronic liver disease in the United States and worldwide. Though nonalcoholic fatty liver per se may not be independently associated with an increased risk for all-cause mortality, it is associated with a number of harmful metabolic risk factors, such as type 2 diabetes mellitus, hyperlipidemia, obesity, a sedentary lifestyle, and an unhealthy diet. The fibrosis stage is a predictor of all-cause mortality in NAFLD. Mortality in individuals with NAFLD has been steadily increasing, and the most common cause-specific mortality for NAFLD is cardiovascular disease, followed by extra-hepatic cancer, liver-related mortality, and diabetes. High-risk profiles for mortality in NAFLD include PNPLA3 I148M polymorphism, low thyroid function and hypothyroidism, and sarcopenia. Achieving weight loss through adherence to a high-quality diet and sufficient physical activity is the most important predictor of improvement in NAFLD severity and the benefit of survival. Given the increasing health burden of NAFLD, future studies with more long-term mortality data may demonstrate an independent association between NAFLD and mortality.
Citations
Citations to this article as recorded by
Dietary vitamin E intake in metabolic dysfunction–associated steatotic liver disease and all-cause/cause-specific mortality Donghee Kim, Pojsakorn Danpanichkul, Karn Wijarnpreecha, Aijaz Ahmed European Journal of Gastroenterology & Hepatology.2026; 38(1): 63. CrossRef
Secondary Growth Hormone Deficiency That Developed into Cirrhosis after Several Years of Interrupted Growth Hormone Replacement Therapy Ayana Sueki, Daisuke Kaya, Shinsaku Nagamatsu, Chisa Yamamoto, Kohei Ohta, Yuya Matsuo, Yuya Nishio, Yusuke Komeda, Shoma Kikukawa, Kyohei Matsuura, Hideki Matsuo, Masakazu Uejima, Kei Moriya Internal Medicine.2025; 64(3): 387. CrossRef
Liver Cancer Risk Across Metabolic Dysfunction-Associated Steatotic Liver Disease and/or Alcohol: A Nationwide Study Byungyoon Yun, Heejoo Park, Sang Hoon Ahn, Juyeon Oh, Beom Kyung Kim, Jin-Ha Yoon American Journal of Gastroenterology.2025; 120(2): 410. CrossRef
The Fibrosis-4 index predicts all-cause mortality in a cohort of patients at high cardiovascular risk partly through glomerular filtration rate reduction Antonio Mirijello, Gabriella Pacilli, Antonio Siena, Antonio Mangiacotti, Maria Maddalena D'Errico, Daria Dilalla, Olga Lamacchia, Andrea Fontana, Massimiliano Copetti, Pamela Piscitelli, Giovanni Targher, Salvatore A. De Cosmo Nutrition, Metabolism and Cardiovascular Diseases.2025; 35(1): 103768. CrossRef
Secondhand Smoke Exposure and Metabolic Dysfunction-associated Steatotic Liver Disease in US Adolescents Donghee Kim, Brandon J. Perumpail, Pojsakorn Danpanichkul, Karn Wijarnpreecha, Aijaz Ahmed Clinical Gastroenterology and Hepatology.2025; 23(4): 665. CrossRef
Letter: Towards Better Intervention Strategies for MASLD and MetALD—What Are We Missing? Authors' Reply Yewan Park, Jooyi Jung, Gi‐Ae Kim Alimentary Pharmacology & Therapeutics.2025; 61(2): 400. CrossRef
Red cell distribution width/platelet ratio predicts decompensation of metabolic dysfunction-associated steatotic liver disease-related compensated advanced chronic liver disease Ming-Hua Zheng, Amedeo Lonardo World Journal of Gastroenterology.2025;[Epub] CrossRef
PNPLA3 is one of the bridges between TM6SF2 E167K variant and MASLD: Correspondence to editorial on “TM6SF2 E167K variant decreases PNPLA3-mediated PUFA transfer to promote hepatic steatosis and injury in MASLD” Baokai Sun, Likun Zhuang Clinical and Molecular Hepatology.2025; 31(1): e67. CrossRef
Role of noninvasive tests on the prediction of hepatocellular carcinoma in nonalcoholic fatty liver disease patients without cirrhosis: a systematic review and meta-analysis of aggregate and individual patient data Nanicha Siriwong, Supachaya Sriphoosanaphan, Pakanat Decharatanachart, Tanat Yongpisarn, Stephen J. Kerr, Sombat Treeprasertsuk, Thodsawit Tiyarattanachai, Terapap Apiparakoon, Hannes Hagström, Camilla Akbari, Mattias Ekstedt, Terry Cheuk-Fung Yip, Grace European Journal of Gastroenterology & Hepatology.2025; 37(3): 358. CrossRef
Unmet needs of metabolic dysfunction – Associated “fatty or steatotic” liver disease Yu-Ming Cheng, Shao-Wen Wang, Ching Wang, Chia-Chi Wang Tzu Chi Medical Journal.2025; 37(2): 152. CrossRef
Association Between Handgrip Strength and Cardiovascular Disease Risk in MASLD: A Prospective Study From UK Biobank Tae Seop Lim, Sujin Kwon, Sung A. Bae, Hye Yeon Chon, Seol A. Jang, Ja Kyung Kim, Chul Sik Kim, Seok Won Park, Kyoung Min Kim Journal of Cachexia, Sarcopenia and Muscle.2025;[Epub] CrossRef
Metabolic dysfunction-associated steatotic liver disease (MASLD): a systemic disease with a variable natural history and challenging management Luigi Elio Adinolfi, Aldo Marrone, Luca Rinaldi, Riccardo Nevola, Antonio Izzi, Ferdinando Carlo Sasso Exploration of Medicine.2025;[Epub] CrossRef
The relationship between serum uric acid level and non-alcoholic fatty liver disease in northern China: a retrospective cohort study Qian He, Xinyue Liu, Guoyong Ding, Yiying Wang, Xiaoting Luo, Wenyuan Cao, Weijia Xing BMC Public Health.2025;[Epub] CrossRef
Novel pyranopyridine derivatives and their radiolabeled nanoconjugates: An augmented approach for targeted cancer theranostics Hesham A. Shamsel-Din, Mohamed M. Swidan, Ahmed B. Ibrahim, Mohamed A. Motaleb, Tamer M. Sakr Journal of Drug Delivery Science and Technology.2025; 107: 106802. CrossRef
Metabolic dysfunction-associated steatotic liver disease in adults Daniel Q. Huang, Vincent W. S. Wong, Mary E. Rinella, Jerome Boursier, Jeffrey V. Lazarus, Hannele Yki-Järvinen, Rohit Loomba Nature Reviews Disease Primers.2025;[Epub] CrossRef
Elevated red blood cell folate levels are associated with metabolic dysfunction-associated steatotic liver disease: results from NHANES 2017–2020 Xin Liao, Song Yu, Lin Wang, Ruyue Zhang, Ke Yu Frontiers in Physiology.2025;[Epub] CrossRef
Association of High‐Sensitivity Troponins in Metabolic Dysfunction‐Associated Steatotic Liver Disease With All‐Cause and Cause‐Specific Mortality Donghee Kim, Pojsakorn Danpanichkul, Karn Wijarnpreecha, George Cholankeril, Aijaz Ahmed Alimentary Pharmacology & Therapeutics.2025; 61(11): 1785. CrossRef
Addressing the burden of steatotic liver disease: The role of transient elastography: Correspondence to editorial on “Current burden of steatotic liver disease and fibrosis among adults in the United States, 2017-2023” Donghee Kim, Pojsakorn Danpanichkul, Karn Wijarnpreecha, George Cholankeril, Rohit Loomba, Aijaz Ahmed Clinical and Molecular Hepatology.2025; 31(2): e180. CrossRef
The burden of steatotic liver disease before and during the COVID-19 pandemic: Correspondence to editorial on “Current burden of steatotic liver disease and fibrosis among adults in the United States, 2017-2023” Donghee Kim, Pojsakorn Danpanichkul, Karn Wijarnpreecha, George Cholankeril, Rohit Loomba, Aijaz Ahmed Clinical and Molecular Hepatology.2025; 31(2): e183. CrossRef
Current burden of steatotic liver disease and fibrosis among adults in the United States, 2017–2023 Donghee Kim, Pojsakorn Danpanichkul, Karn Wijarnpreecha, George Cholankeril, Rohit Loomba, Aijaz Ahmed Clinical and Molecular Hepatology.2025; 31(2): 382. CrossRef
Associations between non-insulin-based insulin resistance surrogate markers and liver-related outcomes in metabolic dysfunction-associated steatotic liver disease: a nationwide cohort study in South Korea Sang Yi Moon, Minkook Son, Yeo Wool Kang, Myeongseok Koh, Jong Yoon Lee, Yang Hyun Baek BMC Gastroenterology.2025;[Epub] CrossRef
Response to the Letter to the Editor: What Is the Optimal Anti‐Diabetic Regimen Among CHB and T2DM Patients? Beom Kyung Kim Liver International.2025;[Epub] CrossRef
The new definition of metabolic dysfunction-associated steatotic liver disease: the role of ultrasound and elastography Xinrui Jin, Terry Cheuk-Fung Yip, Grace Lai-Hung Wong, Vincent Wai-Sun Wong, Jimmy Che-To Lai Ultrasonography.2025; 44(3): 189. CrossRef
Association between dietary amino acid intake and the risk of metabolic dysfunction-associated steatotic liver disease Ruoqi Zhou, Xinrong Zhang, Xinxin Liu, Rui Huang, Yuwei Wang, Dajing Xia, Xue Li, Yihua Wu, Yu Shi Journal of Advanced Research.2025;[Epub] CrossRef
Prevalence and Risk Factors of Metabolic-Associated Fatty Liver Disease in Children with Down Syndrome at a Tertiary Care Center Maria D. Karaceper, Maria-Jose Villegas, Sanathan Sadh, Sierra Kawesa, Jamie Strain, Asha Nair, Alissa Dupuis, Mary Pothos, Ming-Hua Zheng, Mohit Kehar Journal of Clinical Medicine.2025; 14(9): 3239. CrossRef
The Role of Global Physical Capacity Score in Key Parameters of Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) Nicola Verrelli, Caterina Bonfiglio, Isabella Franco, Claudia Beatrice Bagnato, Dolores Stabile, Endrit Shahini, Antonella Bianco Journal of Clinical Medicine.2025; 14(11): 3821. CrossRef
Microwave Thermosphere Ablation Versus Radiofrequency Ablation in Hepatocellular Carcinoma: Optimizing Treatment Strategies for Tumor Size and Malignancy Grade Hideyuki Tamai, Jumpei Okamura Hepatology Research.2025; 55(9): 1274. CrossRef
Association between impaired sensitivity to thyroid hormones and sedentary behavior: a cross-sectional study Hangzhou Yang, Jie Kang, Lingkang Dong, Zihan Lin, Qixian Lin, Bo Wu Frontiers in Medicine.2025;[Epub] CrossRef
ECM formation and degradation during fibrosis, repair, and regeneration Alejandro E. Mayorca-Guiliani, Diana Julie Leeming, Kim Henriksen, Joachim Høg Mortensen, Signe Holm Nielsen, Quentin M. Anstee, Arun J. Sanyal, Morten A. Karsdal, Detlef Schuppan npj Metabolic Health and Disease.2025;[Epub] CrossRef
Current burden of MASLD, MetALD, and hepatic fibrosis among US adults with prediabetes and diabetes, 2017–2023 Donghee Kim, Rohit Loomba, Aijaz Ahmed Clinical and Molecular Hepatology.2025; 31(3): e235. CrossRef
The Burden of Nonmalignant Metabolic Dysfunction‐Associated Steatotic Liver Disease in the Western Pacific Region: A Systematic Analysis From 1990 to 2021 Qichao Ge, Yuan Lin, Mingwang Wang, Jianwei Zhu, Qingqing Zhang, Junjun Wang, Yufei Yang, Hanjing Zhangdi, Yuecheng Guo, Shanjuan Wang, Lungen Lu Food Science & Nutrition.2025;[Epub] CrossRef
The association between serum pinenes and non-alcoholic fatty liver disease based on the NHANES 2013–2014 Tuo Xiao, Xue Xing, Lulu Sun, Jin Shang Ecotoxicology and Environmental Safety.2025; 302: 118712. CrossRef
Long-Term Feasibility and Outcomes of a Digital Health Program to Improve Liver Fat and Cardiometabolic Markers in Individuals With Nonalcoholic Fatty Liver Disease: Prospective Single-Arm Feasibility Study Sigridur Björnsdottir, Hildigunnur Ulfsdottir, Elias Freyr Gudmundsson, Bartosz Dobies, Kolbrun Sveinsdottir, Ari Pall Isberg, Gudlaug E A Magnusdottir, Thrudur Gunnarsdottir, Tekla Karlsdottir, Gudlaug Bjornsdottir, Sigurdur Sigurdsson, Saemundur Oddsson JMIR Cardio.2025; 9: e72074. CrossRef
Reliability of Ultrasonic Hepatorenal Indices in Assessing Hepatic Steatosis: A Systematic Review and Meta‐Analysis Jin‐Li Wang, Jian Dong, Si‐Rui Wang, Chun‐Li Cao, Jin Tong, WenXiao Li, Ting‐Ting Du, Ting‐Ting He, Xiao‐Wu Yuan, Jun Li, Hong Zhai Journal of Clinical Ultrasound.2025;[Epub] CrossRef
The effects of ellagic acid in metabolic dysfunction-associated steatotic liver disease (MASLD) patients: a randomized, add-on, double-blind, controlled trial Mohammad Mahmoudi Azar, Matin Shirazinia, Mohsen Nematy, Vafa Baradaran Rahimi, Motahare Bateni, Fateme Tafaghodi Piadeh Gheibi, Farnood Rajabzadeh, Ladan Goshayeshi, Sara Honari, Mehran Mottahedi, Vahid Reza Askari Inflammopharmacology.2025; 33(9): 5583. CrossRef
Comparison of the Efficacy of Dipeptidyl Peptidase-4 Inhibitors and Sodium-Glucose Cotransporter-2 Inhibitors in Diabetic Patients with Steatotic Liver Disease Yunmi Ko, Moon Haeng Hur, Youngsu Park, Jeayeon Park, Hyunjae Shin, Yun Bin Lee, Eun Ju Cho, Jeong-Hoon Lee, Su Jong Yu, Jung-Hwan Yoon, Yoon Jun Kim Gut and Liver.2025; 19(5): 758. CrossRef
Extrahepatic manifestation of metabolic dysfunction-associated steatotic liver disease Anoushka Shenoy, Aijaz Ahmed, Donghee Kim Metabolism and Target Organ Damage.2025;[Epub] CrossRef
Social Determinants of Health in Metabolic Dysfunction‐Associated Steatotic Liver Disease and All‐Cause/Cause‐Specific Mortality Donghee Kim, Pojsakorn Danpanichkul, Karn Wijarnpreecha, Rohit Loomba, Aijaz Ahmed Alimentary Pharmacology & Therapeutics.2025;[Epub] CrossRef
Placebo Rates in Metabolic Dysfunction–Associated Steatohepatitis Clinical Trials: A Systematic Review and Meta-Analysis Francisco Idalsoaga, Luis Antonio Díaz, Saleh Alghsoon, Bishoy Lawendy, Neha Sharma, Hailemichael Desalegn, Yuhong Yuan, My Ha, Jessica Le, John K. MacDonald, Marco Arrese, Rohit Loomba, Vipul Jairath, Mohammad Qasim Khan, Juan Pablo Arab Clinical Gastroenterology and Hepatology.2025;[Epub] CrossRef
Editorial: Understanding How Social Determinants of Health Impact Mortality in MASLD—Insights From a National Analysis. Authors' Reply Donghee Kim, Pojsakorn Danpanichkul, Karn Wijarnpreecha, Rohit Loomba, Aijaz Ahmed Alimentary Pharmacology & Therapeutics.2025;[Epub] CrossRef
Quick glance at 'metabolic dysfunction associated steatotic liver disease' therapeutics: Targets, trials, and trends George S Zacharia, Muhammad H Ashraf, Franklin Sosa, Anu Jacob, Harish Patel World Journal of Gastrointestinal Pharmacology and Therapeutics.2025;[Epub] CrossRef
Cost‐effectiveness study of FIB‐4 followed by transient elastography screening strategy for advanced hepatic fibrosis in a NAFLD at‐risk population Huiyul Park, Eileen L. Yoon, Mimi Kim, Sun‐Hong Kwon, Donghee Kim, Ramsey Cheung, Hye‐Lin Kim, Dae Won Jun Liver International.2024; 44(4): 944. CrossRef
Proposal of a Novel Serological Algorithm Combining FIB-4 and Serum M2BPGi for Advanced Fibrosis in Nonalcoholic Fatty Liver Disease Sang Yi Moon, Yang Hyun Baek, Se Young Jang, Dae Won Jun, Ki Tae Yoon, Young Youn Cho, Hoon Gil Jo, Ae Jeong Jo Gut and Liver.2024; 18(2): 283. CrossRef
Editorial: Using machine learning to predict significant fibrosis in metabolic dysfunction‐associated steatotic liver disease Richie Manikat, Aijaz Ahmed, Donghee Kim Alimentary Pharmacology & Therapeutics.2024; 59(7): 893. CrossRef
Steatotic liver disease‐associated all‐cause/cause‐specific mortality in the United States Donghee Kim, Karn Wijarnpreecha, George Cholankeril, Aijaz Ahmed Alimentary Pharmacology & Therapeutics.2024; 60(1): 33. CrossRef
Estimated pulse wave velocity in metabolic dysfunction‐associated steatotic liver disease and all‐cause/cause‐specific mortality Donghee Kim, Richie Manikat, Karn Wijarnpreecha, George Cholankeril, Aijaz Ahmed Journal of Gastroenterology and Hepatology.2024; 39(9): 1950. CrossRef
Perspective article: determinants and assessment of cardiovascular risk in steatotic liver disease owing to metabolic dysfunction-addressing the challenge Mohamad Jamalinia, Amedeo Lonardo Metabolism and Target Organ Damage.2024;[Epub] CrossRef
Accurate prediction of all-cause mortality in patients with metabolic dysfunction-associated steatotic liver disease using electronic health records Ignat Drozdov, Benjamin Szubert, Ian A. Rowe, Timothy J. Kendall, Jonathan A. Fallowfield Annals of Hepatology.2024; 29(5): 101528. CrossRef
The synergistic impact of type 2 diabetes and MASLD on cardiovascular, liver, diabetes‐related and cancer outcomes David R. Riley, Theresa Hydes, Gema Hernadez, Sizheng S. Zhao, Uazman Alam, Daniel J. Cuthbertson Liver International.2024; 44(10): 2538. CrossRef
The Impact of Body Composition on the Prognosis of Nonalcoholic Fatty Liver Disease Do Seon Song Gut and Liver.2024; 18(4): 562. CrossRef
Association of nonalcoholic fatty liver disease with new-onset atrial fibrillation stratified by age groups Eun Ju Cho, Goh Eun Chung, Jeong-Ju Yoo, Yuri Cho, Kyu Na Lee, Dong Wook Shin, Yoon Jun Kim, Jung-Hwan Yoon, Kyungdo Han, Su Jong Yu Cardiovascular Diabetology.2024;[Epub] CrossRef
Metabolic Dysfunction-Associated Steatotic Liver Disease in Japan: Prevalence Trends and Clinical Background in the 10 Years before the Coronavirus Disease 2019 Pandemic Akira Sato, Yumiko Oomori, Rika Nakano, Tomokazu Matsuura Medicina.2024; 60(8): 1330. CrossRef
Contemporary awareness of nonalcoholic fatty liver disease and viral hepatitis based on the stage Donghee Kim, Richie Manikat, Karn Wijarnpreecha, George Cholankeril, Aijaz Ahmed The American Journal of the Medical Sciences.2024; 368(6): 685. CrossRef
High sensitivity troponins and mortality in the population with metabolic dysfunction-associated steatotic liver disease Jingjing Hu, Yuteng Du, Yidan Zhou, Huiying Wang Scientific Reports.2024;[Epub] CrossRef
Impact of Korean Military Service on the Prevalence of Steatotic Liver Disease: A Longitudinal Study of Pre-enlistment and In-Service Health Check-Ups Jaejun Lee, Jae Hyeop Jung, Sung Jun Choi, Beomman Ha, Hyun Yang, Pil Soo Sung, Si Hyun Bae, Jeong-A Yu Gut and Liver.2024; 18(5): 888. CrossRef
Vaccinium spp. Berries in the Prevention and Treatment of Non-Alcoholic Fatty Liver Disease: A Comprehensive Update of Preclinical and Clinical Research Ewelina Książek, Zuzanna Goluch, Marta Bochniak Nutrients.2024; 16(17): 2940. CrossRef
Metabolic bariatric surgery, alcohol misuse and liver cirrhosis: a narrative review Matthew L. Basa, Danielle S. Cha, David P. Mitchell, Daniel L. Chan Metabolism and Target Organ Damage.2024;[Epub] CrossRef
Metabolic dysfunction‐associated steatotic liver disease and MetALD increases the risk of liver cancer and gastrointestinal cancer: A nationwide cohort study Yewan Park, Jooyi Jung, Seungbong Han, Gi‐Ae Kim Alimentary Pharmacology & Therapeutics.2024; 60(11-12): 1599. CrossRef
Metabolic Dysfunction-Associated Steatotic Liver Disease Is Associated with Increased Risk of Kidney Cancer: A Nationwide Study Juyeon Oh, Beom Kyung Kim, Jin-Ha Yoon, Hyung Ho Lee, Heejoo Park, Jian Lee, Youngsun Park, Byungyoon Yun, Jinsoo Chung Cancers.2024; 16(18): 3161. CrossRef
Metabolic-associated fatty liver disease is less effective in predicting mortality than non-alcoholic fatty liver disease and metabolic dysfunction-associated steatotic liver disease: Letter to the editor on “Prognosis of biopsy-confirmed metabolic dysfun Yixuan Zhu, Xiaoyan Ma, Wenjing Ni, Yee Hui Yeo, Junping Shi, Jie Li Clinical and Molecular Hepatology.2024; 30(4): 974. CrossRef
Leukocyte telomere shortening in metabolic dysfunction-associated steatotic liver disease and all-cause/cause-specific mortality Donghee Kim, Pojsakorn Danpanichkul, Karn Wijarnpreecha, George Cholankeril, Aijaz Ahmed Clinical and Molecular Hepatology.2024; 30(4): 982. CrossRef
Unraveling the Association of Liver Steatosis and Fibrosis with Vitamin B12: A Cross-Sectional Study Silvia Espina, Diego Casas-Deza, Vanesa Bernal-Monterde, Ana Royo-Esteban, Maria Pilar García-Sobreviela, Pilar Calmarza, Ana B. Martinez-Martinez, Jesús Osada, Jose M. Arbones-Mainar Metabolites.2024; 14(11): 618. CrossRef
Association between Body Fat Distribution and Nonalcoholic Fatty Liver Disease/Fibrosis Based on Race/Ethnicity Donghee Kim, George Cholankeril, Aijaz Ahmed Journal of Obesity & Metabolic Syndrome.2024; 33(4): 326. CrossRef
Nonlinear correlation between fatty liver index and carotid intima media thickness among individuals undergoing health examination Yuanchen Zhou, Shaojie Duan, Rongrui Wang, Jialiang Chen, Shukun Yao Frontiers in Endocrinology.2023;[Epub] CrossRef
The growing burden of non-alcoholic fatty liver disease on mortality Ju-Yeon Cho, Won Sohn Clinical and Molecular Hepatology.2023; 29(2): 374. CrossRef
Discovery of new pyridine heterocyclic hybrids; design, synthesis, dynamic simulations, and in vitro and in vivo breast cancer biological assays Menna M. Abdelshaheed, Hussein I. El Subbagh, Mohamed A. Tantawy, Reem T. Attia, Khairia M. Youssef, Iten M. Fawzy RSC Advances.2023; 13(23): 15689. CrossRef
Synergistic Preventive Effect of Aerobic and Resistance Exercises on Nonalcoholic Fatty Liver Disease Ju-Yeon Cho, Won Sohn Gut and Liver.2023; 17(4): 487. CrossRef
Comment on Clayton-Chubb et al. Understanding NAFLD: From Case Identification to Interventions, Outcomes, and Future Perspectives. Nutrients 2023, 15, 687 Ludovico Abenavoli, Giuseppe La Torre, Natasa Milic Nutrients.2023; 15(13): 2907. CrossRef
Impact of Health Related QoL and Mediterranean Diet on Liver Fibrosis in Patients with NAFLD Nuria Perez-Diaz-del-Campo, Gabriele Castelnuovo, Chiara Rosso, Aurora Nicolosi, Marta Guariglia, Eleonora Dileo, Angelo Armandi, Gian Paolo Caviglia, Elisabetta Bugianesi Nutrients.2023; 15(13): 3018. CrossRef
Aerobic and Resistance Exercise: Synergistic Influence for Nonalcoholic Fatty Liver Disease Ho Soo Chun Gut and Liver.2023; 17(4): 485. CrossRef
From nonalcoholic steatohepatitis, metabolic dysfunction-associated fatty liver disease, to steatotic liver disease: Updates of nomenclature and impact on clinical trials Ming-Lun Yeh, Ming-Lung Yu Clinical and Molecular Hepatology.2023; 29(4): 969. CrossRef
Association of Visceral Fat Obesity, Sarcopenia, and Myosteatosis with Non-Alcoholic Fatty Liver Disease without Obesity Hong-Kyu Kim, Sung-Jin Bae, Min Jung Lee, Eun Hee Kim, Hana Park, Hwi Seung Kim, Yun Kyung Cho, Chang Hee Jung, Woo Je Lee, Jaewon Choe Clinical and Molecular Hepatology.2023; 29(4): 987. CrossRef
Lifestyle of patients with non-alcoholic fatty liver disease: assessment of dietary habits and physical activity T.S. Krolevets, M.I. Syrovenko, M.A. Livzan Russian Journal of Evidence-Based Gastroenterology.2023; 12(4): 43. CrossRef
Current epidemiology of chronic liver disease Richie Manikat, Aijaz Ahmed, Donghee Kim Gastroenterology Report.2023;[Epub] CrossRef
Nonalcoholic fatty liver disease (NAFLD) is a multisystemic disease and a rapidly growing cause of chronic liver disease in children and adults worldwide. Diagnosis and management of extrahepatic manifestations of NAFLD, including cardiovascular disease (CVD), type 2 diabetes mellitus, metabolic syndrome, chronic kidney disease, obstructive sleep apnea, polycystic ovarian syndrome, hypothyroidism, psoriasis, and extrahepatic malignancy are crucial for the treatment of patients with NAFLD. The leading cause of death in NAFLD is primarily from CVD, followed by liver-related mortality, extrahepatic cancer, liver cancer, and diabetes-related mortality. Therefore, clinicians need to identify high-risk patients earlier in the disease course and be aware of the extrahepatic manifestations of NAFLD to improve liver disease outcomes. In this review, we focus on the monitoring and management of the extrahepatic manifestations of NAFLD.
Citations
Citations to this article as recorded by
Association Between Sociodemographic Variables, Healthy Habits, and Stress with Risk Scales for Liver Disease Associated with Metabolic Dysfunction Ángel Arturo López-González, Emilio Martínez-Almoyna Rifá, Hernán Paublini Oliveira, Cristina Martorell Sánchez, Pedro Juan Tárraga López, José Ignacio Ramírez-Manent Life.2025; 15(1): 116. CrossRef
Long-term outcomes and risk modifiers of metabolic dysfunction-associated steatotic liver disease between lean and non-lean populations Pojsakorn Danpanichkul, Kanokphong Suparan, Vitchapong Prasitsumrit, Aijaz Ahmed, Karn Wijarnpreecha, Donghee Kim Clinical and Molecular Hepatology.2025; 31(1): 74. CrossRef
Non alkolik yağlı karaciğer hastalığı ile kafein alımı arasındaki ilişki İzel Akkaya, İlknur Gökçe Yıldırım Sağlık Profesyonelleri Araştırma Dergisi.2025; 7(1): 47. CrossRef
Advances in humanoid organoid-based research on inter-organ communications during cardiac organogenesis and cardiovascular diseases Baoqiang Ni, Lingqun Ye, Yan Zhang, Shijun Hu, Wei Lei Journal of Translational Medicine.2025;[Epub] CrossRef
Association of High‐Sensitivity Troponins in Metabolic Dysfunction‐Associated Steatotic Liver Disease With All‐Cause and Cause‐Specific Mortality Donghee Kim, Pojsakorn Danpanichkul, Karn Wijarnpreecha, George Cholankeril, Aijaz Ahmed Alimentary Pharmacology & Therapeutics.2025; 61(11): 1785. CrossRef
Investigating the Mechanisms of Lycii fructus in Treating Nonalcoholic Fatty Liver Disease and Diabetes Comorbidity Through Network Pharmacology and Molecular Dynamics Peng Sun, Jiahui Song, Yang Liu, Xiujing Li, Yiming Zhang, Yuxing Zhou, Wei Gong Food Science & Nutrition.2025;[Epub] CrossRef
Increased BMD in SLD Patients Without Advanced Hepatic Fibrosis: Evidence From the NHANES 2017–2020 Database Tianhao Wu, Lu Li, Yayuan Mei, Peizhen Lv, Jiawei Cui, Lin Liu, Yuemin Nan, Ang Li, Yu-Chen Fan Canadian Journal of Gastroenterology and Hepatology.2025;[Epub] CrossRef
Advances in Incretin‐Based Therapies for MAFLD: Mechanisms and Clinical Evidence Wenqi Dong, Haiming Zhang, Shaowei Mu, Shuyi Shi, Junli Zhang, Keshu Xu Clinical Pharmacology & Therapeutics.2025;[Epub] CrossRef
Causal Relationship between Psoriasis and Non-Alcoholic Fatty Liver Disease: A Bidirectional Two-Sample Mendelian Randomization Study 恒 杨 Advances in Clinical Medicine.2024; 14(04): 101. CrossRef
Non-alcoholic fatty liver disease: a current challenge of interdisciplinary research E. V. Biryukova Meditsinskiy sovet = Medical Council.2024; (6): 72. CrossRef
Association between obesity phenotypes and non-alcoholic fatty liver: a large population- based study Farid Najafi, Yahya Pasdar, Mehdi Moradi Nazar, Mitra Darbandi BMC Endocrine Disorders.2024;[Epub] CrossRef
Masquerading Spleen: A Perplexing Case of Intrahepatic Splenosis Mimicking Hepatocellular Carcinoma Noriko Ikeda, Yujo Kawashita, Masaki Tateishi, Takashi Ueda, Junzo Yamaguchi, Yasuo Washida, Yoichi Hachitanda Cureus.2024;[Epub] CrossRef
Comparative associations of MASLD and MAFLD with the presence and severity of coronary artery calcification Min Kyu Kang, Jeong Eun Song, Rohit Loomba, Soo Young Park, Won Young Tak, Young Oh Kweon, Yu Rim Lee, Jung Gil Park Scientific Reports.2024;[Epub] CrossRef
Association of Physical Activity With Risk of Liver Fibrosis, Sarcopenia, and Cardiovascular Disease in Nonalcoholic Fatty Liver Disease Ho Soo Chun, Minjong Lee, Hye Ah Lee, Seo Yeong Oh, Hyo Jeong Baek, Jae Won Moon, Yeon Jeong Kim, Jinha Lee, Hyoeun Kim, Hwi Young Kim, Kwon Yoo, Tae Hun Kim, Seung Up Kim Clinical Gastroenterology and Hepatology.2023; 21(2): 358. CrossRef
Positive association between nonalcoholic fatty liver disease and growth hormone deficiency in patients with nonfunctioning pituitary adenoma Yoon-a Hwang, Hye Won Lee, Sang Hoon Ahn, Eun Jig Lee, Cheol Ryong Ku, Seung Up Kim Frontiers in Endocrinology.2023;[Epub] CrossRef
Metabolic dysfunction associated fatty liver disease identifies subjects with cardiovascular risk better than non‐alcoholic fatty liver disease Ho Soo Chun, Minjong Lee, Jae Seung Lee, Hye Won Lee, Beom Kyung Kim, Jun Yong Park, Do Young Kim, Sang Hoon Ahn, Yong‐Ho Lee, Ji‐Hye Kim, Seung Up Kim Liver International.2023; 43(3): 608. CrossRef
Liver transplantation for non-alcoholic fatty liver disease: indications and post-transplant management Sara Battistella, Francesca D’Arcangelo, Marco Grasso, Alberto Zanetto, Martina Gambato, Giacomo Germani, Marco Senzolo, Francesco Paolo Russo, Patrizia Burra Clinical and Molecular Hepatology.2023; 29(Suppl): S286. CrossRef
Extrahepatic Outcomes of Nonalcoholic Fatty Liver Disease Maryam K. Ibrahim, Tracey G. Simon, Mary E. Rinella Clinics in Liver Disease.2023; 27(2): 251. CrossRef
Noninvasive imaging biomarkers for liver fibrosis in nonalcoholic fatty liver disease: current and future Jung Hwan Yu, Han Ah Lee, Seung Up Kim Clinical and Molecular Hepatology.2023; 29(Suppl): S136. CrossRef
Diabetes and cirrhosis: Current concepts on diagnosis and management Laurent Castera, Kenneth Cusi Hepatology.2023; 77(6): 2128. CrossRef
Clinical and histologic factors associated with discordance between steatosis grade derived from histology vs. MRI‐PDFF in NAFLD Beom K. Kim, Nicole Bernstein, Daniel Q. Huang, Nobuharu Tamaki, Kento Imajo, Masato Yoneda, Nancy Sutter, Jinho Jung, Khang Nguyen, Leyna Nguyen, Tracy Le, Egbert Madamba, Lisa Richards, Mark A. Valasek, Cynthia Behling, Claude B. Sirlin, Atsushi Nakajim Alimentary Pharmacology & Therapeutics.2023; 58(2): 229. CrossRef
MAFLD might be better in identifying subjects with sarcopenia or cardiovascular risk than NAFLD: A nationwide study Eugene Han, Ho Soo Chun, Yong‐ho Lee, Jae Seung Lee, Hye Won Lee, Beom Kyung Kim, Jun Yong Park, Do Young Kim, Byung‐Wan Lee, Eun Seok Kang, Bong‐Soo Cha, Sang Hoon Ahn, Seung Up Kim Journal of Gastroenterology and Hepatology.2023; 38(9): 1598. CrossRef
Regression of nonalcoholic fatty liver disease is associated with reduced risk of incident diabetes: A longitudinal cohort study Dong Hyun Sinn, Danbee Kang, Eliseo Guallar, Sung Chul Choi, Yun Soo Hong, Yewan Park, Juhee Cho, Geum-Youn Gwak, Ahmed Mustafa Rashid PLOS ONE.2023; 18(7): e0288820. CrossRef
Fibrotic Burden in the Liver Differs Across Metabolic Dysfunction-Associated Fatty Liver Disease Subtypes Tae Seop Lim, Ho Soo Chun, Soon Sun Kim, Ja Kyung Kim, Minjong Lee, Hyo Jung Cho, Seung Up Kim, Jae Youn Cheong Gut and Liver.2023; 17(4): 610. CrossRef
Magnetic resonance elastography-based prediction model for hepatic decompensation in NAFLD: A multicenter cohort study Beom Kyung Kim, Jaclyn Bergstrom, Rohan Loomba, Nobuharu Tamaki, Namiki Izumi, Atsushi Nakajima, Ramazan Idilman, Mesut Gumussoy, Digdem K. Oz, Ayse Erden, Emily Truong, Ju Dong Yang, Mazen Noureddin, Alina M. Allen, Rohit Loomba, Veeral Ajmera Hepatology.2023; 78(6): 1858. CrossRef
Polycystic ovary syndrome in pediatric obesity and diabetes Elena DONDI, Maria TUFANO, Maria C. VIGONE, Laura LUCACCIONI, Gabriella POZZOBON, Graziamaria UBERTINI, Enza MOZZILLO, Maurizio DELVECCHIO Minerva Pediatrics.2022;[Epub] CrossRef
Mouse liver injury induces hepatic macrophage FGF23 production Pradeep Kumar, Yunshan Liu, Yang Shen, Jacquelyn J. Maher, Francesca Cingolani, Mark J. Czaja, Matias A Avila PLOS ONE.2022; 17(3): e0264743. CrossRef
New Insights into Non-Alcoholic Fatty Liver Disease and Coronary Artery Disease: The Liver-Heart Axis Georgiana-Diana Cazac, Cristina-Mihaela Lăcătușu, Cătălina Mihai, Elena-Daniela Grigorescu, Alina Onofriescu, Bogdan-Mircea Mihai Life.2022; 12(8): 1189. CrossRef
Old and new classes of glucose-lowering agents as treatments for non-alcoholic fatty liver disease: A narrative review Lei Miao, Jing Xu, Giovanni Targher, Christopher D Byrne, Ming-Hua Zheng Clinical and Molecular Hepatology.2022; 28(4): 725. CrossRef
Ultrasound-Based Hepatic Elastography in Non-Alcoholic Fatty Liver Disease: Focus on Patients with Type 2 Diabetes Georgiana-Diana Cazac, Cristina-Mihaela Lăcătușu, Cătălina Mihai, Elena-Daniela Grigorescu, Alina Onofriescu, Bogdan-Mircea Mihai Biomedicines.2022; 10(10): 2375. CrossRef
Intestinal microbiota in the treatment of metabolically associated fatty liver disease Ji-Shuai Wang, Jin-Chun Liu World Journal of Clinical Cases.2022; 10(31): 11240. CrossRef
A Multidisciplinary Approach and Current Perspective of Nonalcoholic Fatty Liver Disease: A Systematic Review Chowdhury F Zaman, Jakia Sultana, Proma Dey, Jui Dutta, Sadia Mustarin, Nuzhat Tamanna, Aditi Roy, Nisha Bhowmick, Mousumi Khanam, Sadia Sultana, Selia Chowdhury, Farjana Khanam, Md Sakibuzzaman, Priyata Dutta Cureus.2022;[Epub] CrossRef
The Role of Resveratrol in Liver Disease: A Comprehensive Review from In Vitro to Clinical Trials Carmine Izzo, Monica Annunziata, Giuseppe Melara, Roberta Sciorio, Marcello Dallio, Mario Masarone, Alessandro Federico, Marcello Persico Nutrients.2021; 13(3): 933. CrossRef
Risk stratification using sarcopenia status among subjects with metabolic dysfunction‐associated fatty liver disease Ho Soo Chun, Mi Na Kim, Jae Seung Lee, Hye Won Lee, Beom Kyung Kim, Jun Yong Park, Do Young Kim, Sang Hoon Ahn, Seung Up Kim Journal of Cachexia, Sarcopenia and Muscle.2021; 12(5): 1168. CrossRef
The Association Between Breastfeeding and Nonalcoholic Fatty Liver Disease in Parous Women: A Nation‐wide Cohort Study Yewan Park, Dong Hyun Sinn, Joo Hyun Oh, Myung Ji Goh, Kyunga Kim, Wonseok Kang, Yong‐Han Paik, Moon Seok Choi, Joon Hyeok Lee, Kwang Cheol Koh, Seung Woon Paik, Geum‐Youn Gwak Hepatology.2021; 74(6): 2988. CrossRef
Association between Fasting Ketonuria and Advanced Liver Fibrosis in Non-Alcoholic Fatty Liver Disease Patients without Prediabetes and Diabetes Mellitus Kiyoung Lim, Minkyu Kang, Junggil Park Nutrients.2021; 13(10): 3400. CrossRef
Fatty Liver Index for Predicting Nonalcoholic Fatty Liver Disease in an Asymptomatic Korean Population Eun-Ju Cho, Gu-Cheol Jung, Min-Sun Kwak, Jong-In Yang, Jeong-Yoon Yim, Su-Jong Yu, Goh-Eun Chung Diagnostics.2021; 11(12): 2233. CrossRef
Non‑alcoholic fatty liver disease and hematologic manifestations (Review) Vlad Pădureanu, Dalia Dop, Alice Drăgoescu, Rodica Pădureanu, Anca Mușetescu, Laurențiu Nedelcu Experimental and Therapeutic Medicine.2021;[Epub] CrossRef
Immunity as Cornerstone of Non-Alcoholic Fatty Liver Disease: The Contribution of Oxidative Stress in the Disease Progression Marcello Dallio, Moris Sangineto, Mario Romeo, Rosanna Villani, Antonino Davide Romano, Carmelina Loguercio, Gaetano Serviddio, Alessandro Federico International Journal of Molecular Sciences.2021; 22(1): 436. CrossRef
Nutraceutical correction in the complex non-drug treatment of metabolic syndrome L.G. Agasarov, T.V. Apkhanova, V.N. Sergeev, A.D. Fesun, M.M. Krukova, V.A. Vasilyeva, D.B. Kulchitskaya, T.V. Konchugova, G.A. Puzyreva, M.Yu. Yakovlev Voprosy kurortologii, fizioterapii i lechebnoi fizicheskoi kul'tury.2021; 98(4): 25. CrossRef
First
Prev
